3. Datamonitor Healthcare. Epilepsy disease coverage. 2015.
4. Featherstone, V. Epilepsy in children and young people. Cerebra - Positively Different. 2010. Available at: http://eprints.hud.ac.uk/id/eprint/14522... accessed 12th March 2018.
5. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/epilepsy/basics/fast-facts.htm Accessed 02 May 2018.
6. Berg AT, Vickrey BG, Testa FM, Levy SR, Shinnar S, DiMario F, et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol. 2006;60:14-17.
7. Berg, A., Shinnar, S., Levy, S., Testa, F., Smith-Rapaport, S., Beckerman, B. Early development of intractable epilepsy in children: a prospective study. Neurology. 2001;56 (11):1445-1452.
8. Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B, et al. Course and outcome of childhood epilepsy: a 15-y follow-up of the Dutch study of epilepsy in childhood. Epilepsia. 2010;51:1189-97.
9. Briviact(R) U.S. Prescribing Information. Brussels, Belgium: UCB, 2018. https://www.briviact.com/briviact-PI.pdf
10. The Epilepsy Foundation of America. About epilepsy basics http://www.epilepsy.com/learn/about-epilepsy-basics accessed accessed 02 May 2018.
11. The Epilepsy Foundation of America. What is epilepsy? http://www.epilepsy.com/learn/epilepsy-101/what-epilepsy accessed 02 May 2018.
12. The Epilepsy Foundation of America. Who gets epilepsy? http://www.epilepsy.com/learn/epilepsy-101/who-gets-epilepsy accessed 02 May 2018
13. Briviact(R) EU Prescribing Information. Brussels, Belgium: UCB, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... accessed 02 May 2018.
CONTACT: For further information: Corporate Communications, FranceNivelle, Global Communications, UCB T +32-2-559-9178,France.nivelle@ucb.com. Jim Baxter, Neurology Communications, UCB, T+32-2-473-78-85-01, jim.baxter@ucb.com. Laurent Schots, Media Relations,UCB, T +32-2-559-92-64, laurent.schots@ucb.com. Investor Relations, AntjeWitte, Investor Relations, UCB T +32-2-559-94-14, antje.witte@ucb.com.Isabelle Ghellynck, Investor Relations, UCBT +32-2-559-9588, isabelle.ghellynck@ucb.com